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costs and/or health-related quality of life. The following complications were se-
lected: cardiovascular disease, peripheral neuropathy, renal disease, retinopathy,
cataract, hypoglycemia, ketoacidosis and adverse birth outcomes. CONCLUSIONS:
Since 2003, 281 reports of 72 studies (including many large, observational studies)
have been published. These reports have substantially increased the available ev-
idence describing complications in T1DM patients. The DCCT/EDIC studies
uniquely provide long-term follow-up (now more than 23 years) of patients man-
aged using strategies that are reasonably representative of contemporary T1DM
management.
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OBJECTIVES: To evaluate the safety of preoperative vitamin D replacement in mild
primary hyperparathyroidism. METHODS: Data were searched from Medline, EM-
BASE, Cochrane CENTRAL and abstracts form annual scientific meetings of various
international bone and mineral societies. Studies examining the effect of preoper-
ative vitamin D replacement in patients with mild primary hyperparathyroidism
(serum calcium 12 mg/dl), irrespective of year and language of the publication
were included in the present meta-analysis. Data were extracted from text of the
included publications or abstract of conferences. RESULTS: The pooled mean dif-
ference for serum calcium, phosphate, intact parathyroid hormone levels and uri-
nary calcium excretion before and after vitamin D replacement in mild primary
hyperparathyroidism were 0.06 mg/dl (95% CI, -0.11, 0.23, Z  0.71, P  0.48), -0.01
mg/dl (95% CI, -0.14, 0.13, Z  0.12, P  0.91), 17.18 pg/ml (95% CI, 1.26, 33.11, Z 
2.11, P  0.03), -56.95 mg/24hr (-104.28, -9.62, Z  2.36, P  0.02) ) respectively.
CONCLUSIONS: Preoperative vitamin D replacement in subjects with mild primary
hyperparathyroidism and vitamin D deficiency is safe. This meta-analysis sup-
ports the recommendation on replacement of vitamin D in subjects with primary
hyperparathyroidism and vitamin D deficiency by Third international workshop on
diagnosis of asymptomatic primary hyperparathyroidism.
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OBJECTIVES: Pasireotide is a novel, injectable multireceptor-targeted somatostatin
analogue that binds with high affinity to four of the five somatostatin receptors. It
has been commercially available in Europe since May 2012 and is the first pituitary-
targeted medical therapy indicated for adult patients with Cushing’s disease (CD)
for whom surgery has failed or is not an option. This analysis aims to quantify the
budget impact (BI) of utilizing pasireotide as second-line therapy in CD in Germany.
METHODS: A thorough chart audit was conducted to analyze resource utilization
and market shares of standard of care in CD. Epidemiology, treatment response
complications and adverse event (AE) data were derived from published literature.
Pasireotide data were taken from a Phase III clinical trial. German tariffs for each
resource were then applied to an Excel-based model to compare utilization and
costs with and without the introduction of pasireotide (net BI) for patients with CD
over a 5-year horizon from the German health care system. RESULTS: Applying a
CD prevalence rate of 39 per million and the treatment success of first-line therapy,
fewer than 200 patients with CD are eligible for pasireotide treatment in Germany.
Assuming that pasireotide in years 1–5 will have a market share of 8%, 15%, 23%,
25% and 26%, the net BI is 812,769€, 549,676€, 1,553,976€, 2,088,511€ and 2,209,948€,
respectively. Budget impact is reduced by early identification of pasireotide non-
responders, low cost of treating pasireotide AEs, and potential displacement of
second-line surgical treatments such as bilateral adrenalectomy. Pasireotide BI
may be further minimized if offsets due to lower consumption of health care re-
sources in controlled patients are considered. CONCLUSIONS: The introduction of
pasireotide into the German health care system will result in clinical benefits for
CD patients associated with a limited and predictable BI.
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OBJECTIVES: Linagliptin is a new oral hypoglycaemiant agent (OHA) from the class
of dipeptidyl peptidase 4 (DPP-4) inhibitors, mostly excreted by biliary pathway,
that has no contra-indication in renal impaired patients. Linagliptin in indicated
for dual therapy (add on to metformin) and for triple therapy (add on to metformin
and Sulfamides).”. The aim of this study is to estimate the potential budget impact
of linagliptin (either as mono substance or in combination with metformin) from
most current DPP-4 inhibitor prescribing patterns. METHODS: A budget impact
model was developed from a French payer perspective. The model focused on
drugs and insulin administration costs. Three prescription patterns were consid-
ered for linagliptin treatment initiation: substitution without treatment intensifi-
cation, substitution with treatment intensification and initiation in naïve patients.
Treatment initiation data were obtained via retrospective analysis of 2011 prescrib-
ing data from the Thales database. DPP-4 inhibitors latest entrants (saxagliptin/
vildagliptin-metformin combinations) were used as benchmark for linagliptin. For
analysis purpose, the daily cost of linagliptin was assumed at market average
(1.19€/day exfactory). RESULTS: Considering a virtual cohort of 10,000 patients
treated with linagliptin (mono or combination with metformin), the whole treat-
ment cost over 5 years would be 21,717 k€ compared with 18,996 k€ for a cohort of
the same size treated with current alternatives. Benefits were observed among
patients receiving triple therapy mainly because of competition with substitution
of more expensive drugs such as GLP1 analogues and insulins. Sensitivity analysis
showed that deploying the “add on to insulin indication” could reduce the budget
impact up to 8 %. CONCLUSIONS: The estimated budget impact of linagliptin will
be close to neutrality, as around 87.5 % of linagliptin costs are already offset by
substitutions, based on conservative assumptions.
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OBJECTIVES: To measure the economic impact of insulin analogues, and its partial
substitution by human insulin on the Mexican Institute of Social Security (IMSS)
health expenditure METHODS: Considering similar efficacy in both types of insu-
lin, a retrospective analysis on the supply department of the Administrative Direc-
torate database, at the IMSS, was conducted. The consumed volume during 2011
was identified; all types of insulin included in the IMSS formulary were incorpo-
rated to the analysis. The information gathered was stratified by analogue and
human insulin. The share in volume and monetary values was established for all
insulin at the institutional market. The information was traspolated to 2012 prices.
The impact on the expenditure was analyzed when analogue insulin was substi-
tuted by human insulin in 25 and 50%. Potential savings for the IMSS were obtained
if analogue insulin consumption is reduced by substituting it with human insulin.
An exchange rate of 14 MXN to 1 USD updated to May the 30, 2012 was considered
RESULTS: The IMSS total expense in insulin in 2011 reached $41,281,671.26 USD,
76.3% was expend on analogue insulin whilst it only represented 19.3% of all insu-
lin purchased in 2011. The information transpolated to 2012 prices, showed
$43,208,169.84 USD or an increase by 4.6% in expenditure considering the same
institutional insulin market share. Substituting 25% of the volume of analogue
insulin with human insulin may lead to savings in $7,971,446.06 USD equivalent to
18.4% of the expected expenditure for 2012, meanwhile substituting 50% of the
volume of analogue insulin with human insulin leads to potentials savings by
$15,942,892.11 USD, equivalent to 36.9% of the expected expenditure for 2012
CONCLUSIONS: Substituting analogue insulin by human insulin in 50% is associ-
ated to a drop in 36.9% in the total insulin expenditure at the IMSS not affecting
health outcomes in diabetic patients
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OBJECTIVES: To compare health care resources utilization and corresponding
costs in adults patients with painful Diabetes Peripheral Neuropathy (pDPN) who
initiated treatment with pregabalin or gabapentin as an add-on therapy to usual
care in Spanish daily medical practice setting.METHODS:A retrospective database
study was designed including systematically all medical records of adult patients,
with pDPN (ICD-9-CM codes; 250.6-357.2), both gender, who were covered by the
BSA health plan in years 2006-2009, and that initiated treatment with pregabalin or
gabapentin as an add-on therapy for the first time. Socio-demographics, co-mor-
bidity burden index, treatment duration, all type health care resources and days
off-work due to pDPN were assessed. Societal perspective was applied in estimat-
ing costs. Comparisons of costs were adjusted by age, sex and the Charlson index of
co-morbidity. RESULTS: A total of 395 medical records were eligible for analysis:
227 (57.5%) with pregabalin and 168 (42.5%) with gabapentin. No significant differ-
ences were observed in previous exposition to analgesics: pregabalin 2.7 (1.9) drugs;
gabapentin 2.6 (1.9), p0.05. However, concomitant use of analgesics was higher in
gabapentin cohort; 3.9 (2.2) vs. 3.1 (2.1); p0.05, mainly due to a higher utilization of
non-narcotics (78.0% vs. 71.8%; p0.05) and opioids (32.7% vs. 28.6%; p0.05).
Health care costs accounted for the 59.2% of total cost, with a mean cost per patient
of €2,476. Adjusted mean (95% CI) total costs were significantly lower in patients
receiving pregabalin [€2,003 (1,427-2,579)] compared with those treated with gaba-
pentin [€3,127 (2,463-3,790)], p0.013, mainly due to lower health care costs; €1,312
(1,192-1,432) versus €1,675 (1,537-1,814), respectively (p0.001). Less use of con-
comitant analgesics, medical visits and days off-work accounted for such findings.
CONCLUSIONS: Treatment of pDPN patients with pregabalin add-on to usual care
could be a cost-saving alternative from the societal perspective when compared
with gabapentin in real world settings in Spain.
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OBJECTIVES: To evaluate the health care cost for the management of diabetes
along with other co-morbidities condition before and after counseling. METHODS:
A Prospective interventional study was conducted in the community setup of
Warangal, India for a period of four months. Only the educated Diabetic patients
with other comorbidities were enrolled in the study. The data collected were cost of
medications, lab tests, consultation fee, transportation cost. The average total
health care cost was calculated based on the previous two months expenses of
each patient before and after counseling. RESULTS: A total of 100 patients were
evaluated in the study period. Out of 100 patients, majorities were in the age group
of 41-61 yrs 66(66%) and men 63(63%) followed by women 37(37%). Most of the
patients were diabetes with hypertension, dyslipidemia. The average cost of med-
ications per patient Rs. 1540(72.81%), the average laboratory cost per patient Rs.
350(16.55%), the average doctors consultation fee per patient Rs.175(8.27%), the
average transportation charges per patient Rs.50(2.36%). The most common drugs
prescribed in the study were Metformin, Glibenclamide, Gliclazide, Insulin,
Ramipril, Amlodipine, Telmisartan, Metoprolol, Hydrochlorothiazide, Furosemide,
Atorvastatin and Aspirin. The most common laboratory test includes FBS/PPBS/
RBS/HbA1C, lipid profiles, urine analysis, Hb, Electrolytes and Sr.Creatinine. The
average total health care cost for two months before and after counseling was
found to be Rs.2115 and Rs.1755 per patient.CONCLUSIONS: In summary this is the
first Indian health care cost study conducted in the community setup. Our study
result shows that there is decreased cost for the management of diabetes along
with other co-morbidities condition after the counseling by 17% to 18% after the
two months follow up. So more prevention efforts and resources are required to
reduce this burden and to provide basic diabetes care in the low- and middle-
income countries.
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OBJECTIVES: With the introduction of the bundled payment model in 2007, a large
number of disease management programs (DMP) were initiated in the Netherlands.
It is hypothesized that bundled payment will improve the quality of care en en-
courages tasks delegation and substitution. As result, health care costs may de-
crease resulting in efficiency improvement of diabetes care. METHODS: We ana-
lyzed insurance claim payments of 24 different insurance agencies of the
Netherlands using data of Vektis. Data of 52 care groups, covering about 50% of the
diabetes type 2 population were used. In total, 61,497 diabetes type 2 patients,
clustered in 3078 GPs, were analyzed in a longitudinal multi-level design. For two
years 32% of the patients (or their GPs) were enrolled in a DMP based on bundled
payment and 21% in a DMP based on management fee whereas the patients of the
control group (47%) stayed in ‘care-as-usual’ (CAU). RESULTS: Results show in-
creasing curative health care costs of Euro 219 per patient from 2008 to 2009. While
controlling for age, sex, comorbidity, and costs at baseline (average yearly costs in
2008 were Euro 4123), the average costs per patient enrolled in DMP based on
bundled payment increased with Euro 288 more compared to CAU. The increase of
costs of DMP based on management fee was not significant different from CAU. The
increase in costs did not vary between health insurance agencies or GPs. Sensitivity
analyses were conducted with a much smaller and therefore less useful 3-year data
set. Substantive conclusions remained the same. CONCLUSIONS: Results showed
an increase in curative health care costs of diabetes patients caused by DMP based
on bundled payment over a period of 2 years. Further research should investigate a
longer time-span to study long-term effects of DMP on costs.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The primary objective of the
analysis was to determine the direct cost components caused by T2DM and its
complications. The relationship between metabolic complications and cost com-
ponents is reported in this presentation. METHODS: Forty centres were selected
from the list of centres in which adult T2DM patients were followed on a routine
basis. These centres were representative of the country, since they were selected
by two-stage cluster sampling. Medical files were reviewed for two to five years
prior to the study. Item prices were obtained from the Ministry of Health and Social
Security Organization of Turkey. Costs are calculated simply as the total of all
frequency-price products (1€  2.321 Turkish Liras; Feb 2012). RESULTS: A total of
942 patients’ data were included in the analysis. During the previous five years,
28.0% of the patients had at least one visit or hospital stay related to metabolic
complications (incl. diabetic ketoacidosis, hyperglycemic hyperosmolar state, hy-
poglycemia) and poor glycemic control. Total annual costs were 549.46€ and
364.52€, in patients with and without metabolic complications, respectively. Costs
related to treatment, laboratory tests and health care services were 270.46€, 61.49€
and 32.57€, respectively, in patients without metabolic complications. Whereas
costs related to treatment, laboratory tests and health care services were signifi-
cantly higher in patients with metabolic complications (383.90€, 88.93€ and 76.64€,
respectively; all p-values0.01). CONCLUSIONS: All components of cost increased
by 35% to 135% with the presence of metabolic complications. Whatever this rela-
tionship is based on (whether a direct association between acute metabolic status
and the costs or an indirect association via the relationship between metabolic
control and systemic complications), better metabolic control will significantly
lower the cost of management of DM.
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OBJECTIVES: An update of health economics analysis of type 2 diabetes mellitus
(T2DM) in adult population in Turkey was performed. The relationship between
chronic long-term complications (i.e. cardiovascular, neurologic, ophthalmic etc)
and cost components is reported in this presentation. METHODS: Forty centres
were selected from the list of centres in which adult T2DM patients were followed
on routine basis. These centres were representative of the country, since they were
selected by two-stage cluster sampling. Medical files were reviewed for two to five
years prior to the study. Collected data included health care utilization items (med-
ical and surgical treatments, laboratory tests, inpatient/outpatient visits, consul-
tations and patient education). Item prices were obtained from the Ministry of
Health and Social Security Organization of Turkey (1€  2.3210 Turkish Liras; Feb
2012). RESULTS:A total of 942 patients’ data were included in the analysis. In 63.7%
of the patients, no visits related to any diabetic complication had been recorded,
thus these patients were regarded as patients without complication. The propor-
tions of patients with one, two and more than two complications were 25.8%, 7.9%
and 2.6%, respectively. Total annual cost, which was found to be 324.27€ in patients
with no systemic complication increased to 512.78€, 641.94€, 817.84€ and 1835.06€
with increasing number of systems involved (from one system to four systems).
CONCLUSIONS: The cost of DM is strongly related with the number of systems
involved by diabetic complications. Since the prevalence of DM is quite high and is
further increasing, prevention and/or delay of complications will be crucial to re-
duce the economic burden of diabetes on the general health care budget. [Integrat-
ing the costs from this analysis and the epidemiologic data from a recently updated
local study (TURDEP-II), a burden of disease model will be developed and distrib-
uted soon].
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OBJECTIVES: Type 2 diabetes imposes a substantial economic burden on society.
The objective of this study was to quantify the association between health care
costs attributable to diabetes and level of glycemic control.METHODS:A retrospec-
tive analysis using a large administrative database and a clinical registry contain-
ing laboratory results was performed. Subjects, aged  45, were diagnosed for
diabetes in 2008 and assigned to one of the 5 groups based upon the percentage of
HbA1c values  7% over the 2-years of follow-up after diagnosis: 80% (excellent-
control), 79%-60% (good), 59%-40% (fair), 39%-20% (poor), 20% (very-poor). The
cost attributable to oral antidiabetic drugs (OAD) and the direct cost due to hospi-
talizations or outpatient services for diabetes or cardiovascular disease were ana-
lyzed. Multivariate analysis was used to control for differences in potential con-
founding factors including age, sex, use of dyslipidemia drugs, use of hypertension
drugs, previous cardiovascular disease and OAD adherence level among the study
groups. RESULTS: Of 8,123 patients included, HbA1c control was excellent in 2,359
(29.0%) patients, good in 870 (10.7%), fair in 853 (10.5%), poor in 998 (12.3%) and
very-poor in 3,043 (37,5%). Adherence to OAD was higher among suboptimal gly-
cemic control patients (from 45.3% in the excellent-control group to 63.9% in the
very-poor control group). Over 2 years, the mean diabetes-related cost was:
€1,947.46 in the excellent-control group; €2,030.68 in that with a good-control; €
2,241.33 with a fair-control; € 2,489.04 with a poor-control; €2,216.75 with a very-
poor-control. After adjustment, the estimated excess cost associated with good-
control, fair-control, poor-control and very-poor-control group was €207.65;
€381.03; €682.28; €417.81 respectively. CONCLUSIONS: Almost half (49.8%) patients
in this study showed a sub-optimal glycemic control. This analysis indicates that
the diabetes-related costs are significantly higher for individuals who have a poor
glycemic control compared with those patients who have an excellent glycemic
control.
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HO MUNICIPAL HOSPITAL, VOLTA REGION, GHANA
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OBJECTIVES: This study explored the pattern and cost of medicines prescribed at a
diabetic clinic in Ho Municipal Hospital, Volta Region, Ghana. METHODS: Cross
sectional in design. A retrospective sampling procedure was used to collect data.
100 computer generated prescriptions were randomly selected from the computer
data base for all OPD cases visiting the diabetic clinic in Ho Municipal Hospital
between the periods of January 1 to December 31, 2011. With the aid of Excel and
SPSS (vers 20), the data generated was analyzed and appropriate measures of cen-
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